This article is a correction to:
Combining different bacteria in vaccine formulations enhances the chance for antiviral cross-reactive immunity: a detailed in silico analysis for influenza A virus
Andrés Bodas-Pinedo1†
Esther M. Lafuente2†
Hector F. Pelaez-Prestel2
Alvaro Ras-Carmona2
Jose L. Subiza3*
Pedro A. Reche2*- 1Children’s Digestive Unit, Institute for Children and Adolescents, Hospital Clinico San Carlos, Madrid, Spain
- 2Department of Immunology & O2, Faculty of Medicine, University Complutense of Madrid, Ciudad Universitaria, Pza. Ramón y Cajal, Madrid, Spain
- 3Inmunotek, Alcalá de Henares, Spain
by Bodas-Pinedo A, Lafuente EM, Pelaez-Prestel HF, Ras-Carmona A, Subiza JL and Reche PA (2023) Front. Immunol. 14:1235053. doi: 10.3389/fimmu.2023.1235053
In the published article, there was an error in Table 1 as published. In row 1, column 2, ¨Accesion” was misspelled. It should be “Accession”. In row 13, column 1, “Klebisella” was misspelled. It should be “Klebsiella”. In addition, in row 9 for SARS-CoV2, column 2 was incorrect (the accession number listed was GCF_000009445, but should have been NC_045512) and column 2 was empty but should have been 12. The corrected Table 1 and its caption appear below.
TABLE 1
Table 1 Amino acid sequences from pathogens and vaccines considered in this study.
In the published article, there was an error in Table 2 as published. “Klebisella” was misspelled. It should be “Klebsiella”. The corrected Table 2 and its caption appear below.
TABLE 2
Table 2 Size of the shared peptidome between bacteria in MV130 and respiratory viruses.
In the published article, there was an error in Table 3 as published. “Klebisella” was misspelled. It should be “Klebsiella”. In addition, the scientific names of bacteria were not in italic. The corrected Table 3 and its caption appear below.
TABLE 3
Table 3 Potential cross-reactive epitopes between MV130 and IAV.
In the published article, there was an error in the legend for Figure 1 as published. HRVA and HRVB, standing for human rhinovirus A and B, respectively, missed the relevant “A” and “B”. The corrected legend appears below.
FIGURE 1
Figure 1 Comparison of peptidomes shared by respiratory viruses and bacteria in MV130. The sets of peptides that are shared between 8 respiratory viruses and each bacterium included in the MV130 formulation were compared and represented using Venn diagrams to visualize the overlaps. The number of peptides in overlapping and non-overlapping regions is indicated. The represented viruses are (from left to right and up to down): IAV: Influenza A virus; IBV: Influenza B virus; HRVA: human rhinovirus A; HRVB: human rhinovirus B; HRVC: human rhinovirus C; RSVA: Respiratory Syncytial virus A; RSVB: Respiratory Syncytial virus B; SARS: SARS-CoV-2. The six bacteria species included in MV130 are indicated and colored as follows: S. pneumoniae (SPN, red); S. aureus (SAU, green); S. epidermidis (SEP, yellow); K. pneumoniae (KPN, blue); B. catarrhalis (BCA, orange); H. influenzae (HIN, purple).
In the published article, there was an error in the Abstract. “Klebisella” was misspelled. It should be “Klebsiella”
A correction has been made to the Abstract. The corrected sentence appears below.
“The bacteria selected in this work were Bacillus Calmette Guerin and those included in the poly-bacterial preparation MV130: Streptococcus pneumoniae, Staphylococcus aureus, Staphylococcus epidermidis, Klebsiella pneumoniae, Branhamella catarrhalis and Haemophilus influenzae.”
In the published article, there was an error in the Methods section. HLA, standing for human leukocyte antigen, was used twice in Methods instead of MHC (major histocompatibility complex). MHCs are known as HLAs in humans, as indicated later in the Results section.
A correction has been made to the Methods section, subsection 2.3 Prediction of T and B cell epitopes. This sentence previously stated:
“Binding of a peptide to a given HLA I molecule was considered to occur at a 2% Rank cutoff given by both RANKPEP and NetMHCpan, which allows selecting weak and strong binders.”
The corrected sentence appears below.
“Binding of a peptide to a given MHC I molecule was considered to occur at a 2% Rank cutoff given by both RANKPEP and NetMHCpan, which allows selecting weak and strong binders.”
Likewise, a correction has also been made to the Methods section, subsection 2.5 Other procedures. This sentence previously stated:
“The percentage of the world population that could respond to CD8 and CD4 T cell epitopes (population coverage) was computed after their HLA binding profiles using a command line version of EPISOPT (44) and the IEDB PPC tool at http://tools.iedb.org/tools/population/iedb_input (45), respectively, considering HLA allele expression for the entire world population.”
The corrected sentence appears below.
“The percentage of the world population that could respond to CD8 and CD4 T cell epitopes (population coverage) was computed after their MHC binding profiles using a command line version of EPISOPT (44) and the IEDB PPC tool at http://tools.iedb.org/tools/population/iedb_input (45), respectively, considering the relevant allele expression for the entire world population.”
The authors apologize for these errors and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Keywords: MV130, bacteria, respiratory viruses, cross-reactivity, epitope, influenza A virus
Citation: Bodas-Pinedo A, Lafuente EM, Pelaez-Prestel HF, Ras-Carmona A, Subiza JL and Reche PA (2023) Corrigendum: Combining different bacteria in vaccine formulations enhances the chance for antiviral cross-reactive immunity: a detailed in silico analysis for influenza A virus. Front. Immunol. 14:1284628. doi: 10.3389/fimmu.2023.1284628
Received: 28 August 2023; Accepted: 30 August 2023;
Published: 08 September 2023.
Edited and Reviewed by:
Tomasz Piotr Wypych, Polish Academy of Sciences, PolandCopyright © 2023 Bodas-Pinedo, Lafuente, Pelaez-Prestel, Ras-Carmona, Subiza and Reche. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Jose L. Subiza, jlsubiza@inmunotek.com; Pedro A. Reche, parecheg@med.ucm.es
†These authors have contributed equally to this work